Global Alpha 1 Antitrypsin Deficiency Treatment Market Strategic Research Report

Scope of the Report

The global Alpha 1 Antitrypsin Deficiency Treatment market size is predicted to grow from US$ 2,456 million in 2025 to US$ 4,400 million in 2032; it is expected to grow at a CAGR of 8.8% from 2026 to 2032.

Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.

Global players of Alpha 1 Antitrypsin Deficiency Treatment include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols, CSL Behring and Kamada Ltd, etc. Top five players occupy for share about 28%. United States is the largest market, with a share about 37%, followed by European Union and China. In terms of product, Augmentation Therapy is the largest segment, with a share over 44%.

This report presents a comprehensive overview of the global Alpha 1 Antitrypsin Deficiency Treatment market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Indication

• Augmentation Therapy
• Cystic Fibrosis(CF)
• Non-CF Bronchiectasis(NCFB)
• Diabetes
• Other

Segment by players, this report covers

• Pfizer
• GlaxoSmithKline
• AstraZeneca
• Boehringer Ingelheim
• Teva Pharmaceutical Industries
• Takeda
• Baxter
• Grifols
• CSL Behring
• Kamada Ltd
• Chiesi Pharmaceuticals
• Kedrion Group
• Vertex Pharmaceuticals
• ProMetic Life Sciences

Segment by Application

• COPD
• Cystic Fibrosis(CF)
• Non-CF Bronchiectasis(NCFB)
• Diabetes

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Alpha 1 Antitrypsin Deficiency Treatment market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in COPD, Cystic Fibrosis(CF), Non-CF Bronchiectasis(NCFB) evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact